Richard T. Maziarz
Experienced in Adult T-Cell Leukemia

Dr. Richard T. Maziarz

University Professional Services
Portland, OR
Experienced
in Adult T-Cell Leukemia
Specialties:Hematology Oncology | Oncology | Hematology
Age:72
Accepting New Patients
Offers Telehealth
42 Years of Experience
OverviewInsuranceLocationsClinical Research

Overview

Richard Maziarz is a Hematologist Oncology specialist and an Oncologist in Portland, Oregon. Dr. Maziarz has been practicing medicine for over 42 years and is rated as an Experienced provider by MediFind in the treatment of Adult T-Cell Leukemia. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Myelodysplastic Syndrome (MDS), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Maziarz is currently accepting new patients.

His clinical research consists of co-authoring 207 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Adult T-Cell Leukemia.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in OR
Hospital Affiliations
Ohsu Hospital And Clinics
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  PacificSource
  •  Humana

Locations

UNIVERSITY PROFESSIONAL SERVICES
3181 Sw Sam Jackson Park Rd, Portland, OR 97239
503-494-8311
Other Locations
UNIVERSITY PROFESSIONAL SERVICES
3303 S Bond Ave, Portland, OR 97239
503-494-8311
UNIVERSITY PROFESSIONAL SERVICES
15700 Sw Greystone Ct, Beaverton, OR 97006
503-494-3442

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Active_not_recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2024
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug, Biological
Study Drugs: SQZ-AAC-HPV, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1/Phase 2
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 17, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Enrollment Status: Terminated
Publish Date: January 30, 2020
Intervention Type: Biological
Study Phase: Phase 3
View 10 Less Clinical Trials

207 Total Publications

Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma.
Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 10, 2024
Similar Doctors
Expertise in
8
conditions
Dr. Brian J. Druker
Hematology Oncology | Oncology
Expertise in
8
conditions
Dr. Brian J. Druker
Hematology Oncology | Oncology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
503-494-8311
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Druker is a Hematologist Oncology specialist and an Oncologist in Portland, Oregon. Dr. Druker has been practicing medicine for over 44 years and is rated as an Elite provider by MediFind in the treatment of Adult T-Cell Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Acute Myeloid Leukemia (AML), and Philadelphia-Negative Chronic Myeloid Leukemia. Dr. Druker is currently accepting new patients.

Expertise in
6
conditions
Dr. Jessica T. Leonard
Hematology | Hematology Oncology | Oncology
Expertise in
6
conditions
Dr. Jessica T. Leonard
Hematology | Hematology Oncology | Oncology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
503-494-8311
Experience:
15+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jessica Leonard is a Hematologist and a Hematologist Oncology provider in Portland, Oregon. Dr. Leonard has been practicing medicine for over 15 years and is rated as a Distinguished provider by MediFind in the treatment of Adult T-Cell Leukemia. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Leonard is currently accepting new patients.

Expertise in
5
conditions
Dr. Adam J. Lamble
Pediatric Hematology Oncology | Hematology | Oncology
Expertise in
5
conditions
Dr. Adam J. Lamble
Pediatric Hematology Oncology | Hematology | Oncology
3181 SW Sam Jackson Park Rd, 
Portland, OR 
503-494-8211
Experience:
14+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Lamble is a Pediatric Hematologist Oncology specialist and a Hematologist in Portland, Oregon. Dr. Lamble has been practicing medicine for over 14 years and is rated as an Advanced provider by MediFind in the treatment of Adult T-Cell Leukemia. His top areas of expertise are Leukemia, Acute Myeloid Leukemia (AML), Childhood Acute Myeloid Leukemia, and Acute Lymphoblastic Leukemia (ALL). Dr. Lamble is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile